Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

Despite the fact that it has been three years since the drug was approved by the FDA, many oncologists still need to be educated regarding Xofigo's benefits beyond pain palliation, The ...

Brits in search of Bayer’s prostate cancer drug Xofigo or Sanofi’s colorectal drug Zaltrap should prepare for disappointment: the National Institute for Health and Care Excellence has said neither of ...

XOFIGO® (radium-223 dichloride) in combination with enzalutamide significantly increased radiological progression-free survival (rPFS) for patients with metastatic castration-resistant prostate cancer ...

New data from the Phase III PEACE III trial showed that XOFIGO ® (radium-223 dichloride) in combination with enzalutamide significantly improved prostate-specific antigen (PSA) response rates (≥90% at ...

US-based Bayer Healthcare Pharmaceuticals, as its executives were quick to point out, has now received three new approvals for cancer indications in the last eight months US-based Bayer Healthcare ...

The National Institute for Health and Care Excellence has expanded the treatment scope of Bayer's Xofigo so that prostate cancer patients not suitable for chemotherapy can now also access the therapy ...

There was mixed news for prostate cancer patients in England and Wales after NHS cost regulators endorsed Bayer’s Xofigo but turned down Ferring’s Firmagon. There was mixed news for prostate cancer ...

DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Xofigo" drug pipelines has been added to ResearchAndMarkets.com's offering. Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly ...